MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
130 patients (estimated)
Sponsors
MacroGenics
Tags
Bispecific Antibody, CD123, CD3
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1691
NCT Identifier
NCT05362773

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.